Stocktoria
INSMED Inc INSM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1991-02-15
INSMED Inc statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -205.6% | -241.5% | -232.5% | -186.4% | -199.0% |
| Net margin | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% |
| FCF margin | -159.6% | -194.1% | -180.1% | -167.2% | -196.6% |
| Return on assets | -56.4% | -45.1% | -56.4% | -29.1% | -35.0% |
| Return on equity | -172.8% | -320.2% | 225.8% | -547.5% | -105.9% |
| Debt / equity | 0.74× | 3.93× | -3.55× | 13.12× | 1.95× |
| Current ratio | 3.83 | 5.45 | 4.12 | 6.69 | 6.19 |
| Revenue growth | 66.7% | 19.2% | 24.4% | 30.2% | 14.6% |
Source: SEC EDGAR filings · CIK 0001104506 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.